/PRNewswire/ Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced.
Gilead has tagged along on Kyverna Therapeutics’ journey as a startup since the beginning, and now the Big Pharma has helped stock up the cell therapy biotech in an $85 million financing round to prepare for a launch into the clinic this year.
/PRNewswire/ Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced.
Aro Biotherapeutics, a Philadelphia, PA-based biotechnology company pioneering the development of tissue-targeted genetic medicines, closed an $88m Series A financing.
The round was led by Northpond Ventures and Cowen Healthcare Investments, with participation from HealthCap, BVF Partners L.P., and Ridgeback Capital. Existing investors, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), BioMotiv, LLC, and Ionis Pharmaceuticals, Inc. In conjunction with the funding, Shaan Gandhi, M.D., D.Phil., director at Northpond Ventures, joined Aro’s board of directors, along with Kevin Raidy, managing partner of Cowen Healthcare Investments.
The company intends to use the funds to advance its lead therapeutic candidates into clinical development, with an initial focus in rare genetic and immune disorders.